Radiation Therapy for ypN0 Breast Cancer

NCT ID: NCT04240548

Last Updated: 2021-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase III randomized study comparing regional nodal irradiation vs. no irradiation for breast cancer patients presenting with node positive disease who turns into node negative after preoperative chemotherapy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm: A

regional nodal irradiation including axillary and supraclavicular lymph node groups along with chest wall or whole breast irradiation

Group Type EXPERIMENTAL

Regional Nodal Irradiation

Intervention Type RADIATION

Arm: B

chest wall or whole breast only irradiation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regional Nodal Irradiation

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* WHO performance status 0-1
* Invasive Breast Cancer with cT1-3 cN1-2 at time of diagnosis
* Axillary nodal involvement can be detected using, clinical examination, ultrasound, CT scan or PET scan
* Pathologic confirmation using, FNAC, core biopsy or excisional biopsy
* ER, PR, Her2 neu and Ki67 status should be available for all patients
* All patients should have received standard preoperative chemotherapy prior to surgery
* At the time of surgery, all patients should have axillary clearance with at least 6 nodes harvested from the axilla
* Patients who have undergone mastectomy or lumpectomy with negative margins with ypN0, ypN0(+i) or ypN0(+mol) are eligible for randomization

Exclusion Criteria

* Poor performance status
* Definitive clinical or radiologic evidence of metastatic disease
* T4 tumors including inflammatory breast cancer
* N3 disease detected clinically or by imaging
* Patients with histologically positive axillary nodes after preoperative chemotherapy
* Positive surgical margin after definitive surgery
* Previous ipsilateral or contralateral breast cancer
* Previous chest wall or breast irradiation
* Second primary cancer
* Active connective tissue disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute, Egypt

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rimoun Ramsis Anis Boutrus

Lecturer of Radiation Oncology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Cancer Institute

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NCI-BC-1/2016

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.